Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer.

Shao Zhi-min,Qingyuan Zhang,Chuan Gui Song,Quchang Ouyang,Zhenzhen Liu,Qiang Liu,Jifeng Feng,Joanne Wing Yan Chiu,Ling-Ming Tseng,Chenxi Qian

Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer.

2021

Shao Zhi-min
Qingyuan Zhang
Chuan Gui Song
Quchang Ouyang
Zhenzhen Liu
Qiang Liu
Jifeng Feng
Joanne Wing Yan Chiu
Ling-Ming Tseng
Chenxi Qian

522Background: In monarchE, abemaciclib (oral CDK4&6 inhibitor) plus endocrine therapy (ET) as adjuvant treatment for HR+, HER2- high risk early breast cancer (EBC), demonstrated a statistically si...

Keywords:

Internal medicine
endocrine therapy
Medicine
Oncology
Adjuvant
Abemaciclib
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations